Zyrtec and Xyzal: FDA Issues Withdrawal Syndrome Warning
MDSpire News
May 19, 2025
You now have access to the trusted editorial news and specialty content you've known from the Conexiant news site—all within the MDSpire experience.
Learn more

The FDA issued a warning about severe pruritus occurring after discontinuation of cetirizine (Zyrtec) or levocetirizine (Xyzal) after long-term use.
Between April 2017 and July 2023, the FDA identified 209 cases of post-discontinuation pruritus, with 197 cases reported in the U.S.
The median time to onset of pruritus after stopping the medications was 2 days, with most patients using them for over 3 months.
Reported cases of pruritus significantly impacted patients' quality of life, with serious outcomes including disability and hospitalization.
The FDA is requiring new warnings about pruritus risk in prescribing information and over-the-counter labels for these medications.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Affiliations:
Specialties:
Areas of Expertise: